Acetylcholinesterase inhibitors

Nutra Pharma Files Updated Provisional Patent for Nerve Agent Counter Measures

Retrieved on:

Friday, July 23, 2021

Branches of biology, Anatomy, Neuroscience, Acetylcholinesterase inhibitors, Nerve agent, Organophosphate, Nerve, Neuron

"We originally announced this project in early 2018, stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma.

Key Points:

"We originally announced this project in early 2018, stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma.
Nerve agents are identified as a class of phosphorus-containing organic chemicals (organophosphates) that may disrupt the transfer of messages to organs through the nerves.
These same receptors are the target of Nutra Pharmas drugs, which may block the action of the nerve agents or minimize the damage that they may cause.
Scientific publications have demonstrated that native and modified neurotoxins can protect nerve cells from early cell death.

Kentucky plant begins nerve-agent rocket destruction campaign

Retrieved on:

Tuesday, July 13, 2021

Chemical weapons, Chemistry, Acetylcholinesterase inhibitors, Blue Grass Chemical Agent-Destruction Pilot Plant, Physical sciences, VX, Bechtel, M55, Nerve agent, Program Executive Office, Assembled Chemical Weapons Alternatives, Tooele Chemical Agent Disposal Facility

RESTON, Va., July 13, 2021 /PRNewswire/ --A Bechtel-led plant in Kentucky has successfully begun destroying its next batch of chemical weapons, just two months after completing a previous campaign.

Key Points:

RESTON, Va., July 13, 2021 /PRNewswire/ --A Bechtel-led plant in Kentucky has successfully begun destroying its next batch of chemical weapons, just two months after completing a previous campaign.
The first M55 rockets containing VX nerve agent were destroyed July 9 at the Blue Grass Chemical Agent-Destruction Pilot Plant (BGCAPP), near Richmond, Kentucky.
"Our team has successfully completed two projectile campaigns involving nerve agent," said Ron Hink, Bechtel Parsons Blue Grass project manager.
"As with previous campaigns, safety will remain the top priority as we begin rocket destruction."

Kentucky plant completes destruction of VX nerve agent weapons in just 4 months

Retrieved on:

Wednesday, June 2, 2021

Acetylcholinesterase inhibitors, Chemistry, Physical sciences, Blue Grass Chemical Agent-Destruction Pilot Plant, Chemical warfare, VX, Nerve agent, Program Executive Office, Assembled Chemical Weapons Alternatives, Tooele Chemical Agent Disposal Facility

The current campaign focused on the eradication of approximately 60 tons of VX nerve agent in 155-milimeter artillery projectiles, which were opened and drained robotically.

Key Points:

The current campaign focused on the eradication of approximately 60 tons of VX nerve agent in 155-milimeter artillery projectiles, which were opened and drained robotically.
The drained toxins undergo a neutralization process using hot water and sodium hydroxide to destroy the VX agent.
The Blue Grass Chemical Agent-Destruction Pilot Plant is safely destroying more than 523 tons of mustard and nerve agent in rockets and projectiles.
Additionally, the main plant destroyed the remaining stockpile of eight-inch nerve agent projectiles, eliminating another class of weapon from the U.S. stockpile.

HJF Receives Patent for Potential Treatment for Nerve Agent Exposure

Retrieved on:

Tuesday, May 11, 2021

Drugs, Acetylcholinesterase inhibitors, Psychoactive drugs, Medicine, Antidotes, Nerve agent, Atropine, Organophosphate, Anticholinergic, Henry M. Jackson Foundation for the Advancement of Military Medicine, Autoinjector

b"BETHESDA, Md., May 11, 2021 /PRNewswire/ --The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) received notice of allowance for a patent from the United States Patent Office (USPO) for a medical countermeasure to organophosphate (OP) nerve agent exposure.

Key Points:

b"BETHESDA, Md., May 11, 2021 /PRNewswire/ --The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) received notice of allowance for a patent from the United States Patent Office (USPO) for a medical countermeasure to organophosphate (OP) nerve agent exposure.
The therapy was shown to be effective even with delayed use following nerve agent exposure.
Currently, treatment for OP exposure is with an anticholinergic agent administered immediately after exposure; thus, military personnel may receive kits containing atropine auto-injectors for use in the event of a nerve-gas attack.\nDr.
Importantly, this new combination therapy also extends the therapeutic window, as it is effective even when administered hours after OP exposure.

Grapefruit USA, Inc. Reports 714% Year-Over-Year Revenue Growth Despite Global Pandemic

Retrieved on:

Monday, April 26, 2021

Appetite stimulants, Entheogens, Euphoriants, Drugs, Psychoactive drugs, Cannabis, Acetylcholinesterase inhibitors, Branches of biology, Tetrahydrocannabinol, Cannabinoid, Hemp

We think we have achieved a very positive result and look forward to continuing to grow our distribution business and to fully usher in the age of Hourglass, our remarkable cannabinoid hemp based-CBD & THC topical time release delivery system.

Key Points:

We think we have achieved a very positive result and look forward to continuing to grow our distribution business and to fully usher in the age of Hourglass, our remarkable cannabinoid hemp based-CBD & THC topical time release delivery system.
In addition, we have been informed by our Canadian Joint Venture/potential acquisition group that their shareholder\xe2\x80\x99s meeting will be held this week as previously reported and at the conclusion of which our discussions will restart immediately.
This was unacceptable to Company management, who raised the issue with the Company\xe2\x80\x99s investor.
The investor agreed that this technical accounting anomaly was an inappropriate result and agreed to assist management in eliminating it.

Taylor Mammon Acquired by American CBD Pioneer GenCanna

Retrieved on:

Monday, March 22, 2021

Turnkey CBD formulator, private label accelerator, and product distributor Taylor Mammon announced today that the company, established in 2018, was acquired by US-based GenCanna, a leading producer of hemp-derived, THC-free, premium CBD and other cannabinoids.

Key Points:

Turnkey CBD formulator, private label accelerator, and product distributor Taylor Mammon announced today that the company, established in 2018, was acquired by US-based GenCanna, a leading producer of hemp-derived, THC-free, premium CBD and other cannabinoids.
Taylor Mammons union with GenCanna has not only fast-tracked this compliance milestone, but now narrows the borders between the US and the UK, positioning Taylor Mammon as a full-service, vertically integrated, worldwide CBD gateway.
GenCannas acquisition of Taylor Mammon positions us for significant international growth and to be a global leader in the CBD arena.
As one of our long-term and valued customers, we admired Taylor Mammons philosophy and approach to CBD, said GenCanna CEO, Andrew Barnett.

Kentucky Plant Begins Destruction of Next Inventory of Nerve Agent Weapons

Retrieved on:

Tuesday, January 12, 2021

Chemical weapons, Chemistry, Acetylcholinesterase inhibitors, Physical sciences, Blue Grass Chemical Agent-Destruction Pilot Plant, VX, Nerve agent, Artillery shells, Chemical warfare, Program Executive Office, Assembled Chemical Weapons Alternatives, Tooele Chemical Agent Disposal Facility

At the Blue Grass Chemical Agent-Destruction Pilot Plant in Richmond, a 155-milimeter artillery projectile filled with VX nerve agent was robotically opened and drained on Jan. 10.

Key Points:

At the Blue Grass Chemical Agent-Destruction Pilot Plant in Richmond, a 155-milimeter artillery projectile filled with VX nerve agent was robotically opened and drained on Jan. 10.
"The Chemical Weapons Convention commits more than 190 nations to the eradication of these weapons.
In early 2020, the plant destroyed the remaining stockpile of 8-inch nerve agent projectiles, eliminating an entire class of weapon from the U.S. stockpile.
After the current campaign, an inventory of rockets containing nerve agent will be all that remains.

Digital Projection's Radiance LED Brings New Life to Church at Liberty Square

Retrieved on:

Tuesday, January 5, 2021

Acetylcholinesterase inhibitors, VX, Chemistry, Radiance, Cartersville, Georgia, Physical sciences

One house of prayer that excels in this is The Church at Liberty Square in Cartersville, Georgia.

Key Points:

One house of prayer that excels in this is The Church at Liberty Square in Cartersville, Georgia.
When they decided to upgrade their youth worship room with an impactful display that could be the centerpiece of their future events, they selected a Radiance LED VX Series display from Digital Projection.
Measuring 219 diagonal, the Radiance LED VX Series 2.5mm display was an easy decision for thediscerning AV integrator.
Find out more about the inspirational Church at Liberty Square community and services on their website at: www.libertysq.org.

Lawsuits Seek Justice for California Family Devastated by Dow’s Dangerous Pesticide

Retrieved on:

Monday, October 19, 2020

Chemistry, Acetylcholinesterase inhibitors, Chlorpyrifos, Soil contamination, Physical sciences, Avenal, California, Pesticide toxicity to bees, Pesticide, Organic compounds

It relates to damage caused by exposure to the dangerous and now widely banned pesticide, made by Dow Chemical under the brand names Lorsban and Dursban.

Key Points:

It relates to damage caused by exposure to the dangerous and now widely banned pesticide, made by Dow Chemical under the brand names Lorsban and Dursban.
Chlorpyrifos was first used in 1965, and since then scientific evidence has shown a link between it and neurological disorders.
When Rafael Jr. was eight months old, the family moved to Avenal, whose water supply was also permeated with the pesticide.
While this lawsuit cant undo the damage done to countless families in central California, it will begin to bring justice to these communities.

Marinus Awarded BARDA Contract to Develop IV Ganaxolone for Treatment of Refractory Status Epilepticus Caused by Nerve Agent Exposure

Retrieved on:

Monday, September 14, 2020

Biotechnology, Pharmaceutical, Health, Acetylcholinesterase inhibitors, Ganaxolone, Ketones, Pregnanes, Sedatives, Biomedical Advanced Research and Development Authority, Nerve agent, Organ systems, Anticonvulsant, Chemical compounds, Neurology

RSE can occur as a result of a variety of serious, acute medical conditions or after exposure to nerve agents.

Key Points:

RSE can occur as a result of a variety of serious, acute medical conditions or after exposure to nerve agents.
Under the contract, Marinus will be responsible for cost-sharing in the amount of $33 million if all development options are completed.
Through this contract, we are demonstrating our commitment to develop innovative anticonvulsant agents, and we believe this funding will help to strengthen our ganaxolone franchise.
On a successful development, BARDA and Marinus may negotiate a procurement agreement for a supply of ganaxolone for potential response to nerve gas exposure threats.